References
- Rosewicz S, Detjen K, Scholz A, von Marschall Z. Interferon-alpha: Regulatory effects on cell cycle and angiogenesis. Neuroendocrinology 2004; 80(Suppl 1)85–93
- Zhang J, Jia Z, Li Q, Wang L, Rashid A, Zhu Z, et al. Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer 2007; 109: 1478–86
- Andreyev HJ, Scott-Mackie P, Cunningham D, Nicolson V, Norman AR, Badve SS, et al. Phase II study of continuous infusion fluorouracil and interferon alfa-2b in the palliation of malignant neuroendocrine tumors. J Clin Oncol 1995; 13: 1486–92
- Nilsson A, Janson ET, Eriksson B, Larsson A. Levels of angiogenic peptides in sera from patients with carcinoid tumours during alpha-interferon treatment. Anticancer Res 2001; 21: 4087–90
- Yao, JC, Ng, C, Hoff, PM, Phan, AT, Hess, K, Chen, H, et al. Improved progression free survival (PFS), and rapid, sustained decrease in tumor perfusion among patients with advanced carcinoid treated with bevacizumab. J Clin Oncol 2005;23:16S, Abstract 4007.
- Kulke, MH, Lenz, HJ, Meropol, NJ, Posey, J, Ryan, P, Picus, J, et al. A phase 2 study to evaluate the efficacy of SU11248 in patients with unresectable neuroendocrine tumors. J Clin Oncol 2005;23:16S, Abstract 4008.
- Bello, CL, Deprimo, SE, Friece, C, Smeraglia, J, Sherman, L, Tye, L, et al. Analysis of circulating biomarkers of sunitinib malate in patients with unresectable neuroendocrine tumors (NET): VEGF, IL-8, and soluble VEGF receptors 2 and 3. J Clin Oncol 2006;24:18S, Abstract 4045.